CLARUS THERAPEUTICS HOLDINGS, INC. Research and Development Expense
CLARUS THERAPEUTICS HOLDINGS, INC. reported Research and Development Expense of $1.23 million for the 3-month period ending 2022-06-30, per its 10-Q filed 2022-08-19.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2022-08-19
- CLARUS THERAPEUTICS HOLDINGS, INC. research and development expense for the quarter ending 2022-06-30 was $1.23M, a 102.81% increase year-over-year.
- CLARUS THERAPEUTICS HOLDINGS, INC. research and development expense for the quarter ending 2022-03-31 was $881.00K, a 27.19% decline year-over-year.
- CLARUS THERAPEUTICS HOLDINGS, INC. research and development expense for the quarter ending 2021-12-31 was $537.00K.
- CLARUS THERAPEUTICS HOLDINGS, INC. research and development expense for the quarter ending 2021-09-30 was $1.27M, a 11.27% decline year-over-year.
- CLARUS THERAPEUTICS HOLDINGS, INC. research and development expense for fiscal 2021 was $3.63M, a 51.38% increase from fiscal 2020.
- CLARUS THERAPEUTICS HOLDINGS, INC. research and development expense for fiscal 2020 was $2.40M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2022-06-30 | $1.23M 10-Q · filed 2022-08-19 | $2.11M 10-Q · filed 2022-08-19 | $2.65M derived: sum of 3 quarters · filed 2022-08-19 | $3.92M derived: sum of 4 quarters · filed 2022-08-19 |
| 2022-03-31 | $881.00K 10-Q · filed 2022-05-16 | $1.42M derived: sum of 2 quarters · filed 2022-05-16 | $2.69M derived: sum of 3 quarters · filed 2022-05-16 | $3.30M derived: sum of 4 quarters · filed 2022-08-19 |
| 2021-12-31 | $537.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $1.81M derived: sum of 2 quarters · filed 2022-03-31 | $2.42M derived: sum of 3 quarters · filed 2022-08-19 | $3.63M 10-K · filed 2022-03-31 |
| 2021-09-30 | $1.27M 10-Q · filed 2021-11-19 | $1.88M derived: sum of 2 quarters · filed 2022-08-19 | $3.09M 10-Q · filed 2021-11-19 | $2.67M derived: sum of 4 quarters · filed 2022-08-19 |
| 2021-06-30 | $606.00K 10-Q · filed 2022-08-19 | $1.82M 10-Q · filed 2022-08-19 | $1.40M derived: sum of 3 quarters · filed 2022-08-19 | $2.83M derived: sum of 4 quarters · filed 2022-08-19 |
| 2021-03-31 | $1.21M 10-Q · filed 2022-05-16 | $790.00K derived: sum of 2 quarters · filed 2022-05-16 | $2.23M derived: sum of 3 quarters · filed 2022-05-16 | |
| 2020-12-31 | -$420.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $1.02M derived: sum of 2 quarters · filed 2022-03-31 | $2.40M 10-K · filed 2022-03-31 | |
| 2020-09-30 | $1.44M 10-Q · filed 2021-11-19 | $2.82M 10-Q · filed 2021-11-19 |